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Abstract
Recurrences of prostate cancer affect approximately one
quarter of patients who have undergone radical prostatectomy.
Reliable factors to predict time to relapse in specific individuals
are lacking. Here, we present a mathematical model that eval-
uates a biologically sensible parameter (a) that can be estimat-
ed by the available follow-up data, in particular by the PSA
series. This parameter is robust and highly predictive for the
time to relapse, also after administration of adjuvant androgen
deprivation therapies. We present a practical computational
method based on the collection of only four postsurgical PSA
values. This study offers a simple tool to predict prostate cancer
relapse. Cancer Res; 76(17); 4941–7. 2016 AACR.
Introduction
Prostate cancer is known to be one of the most slowly growing
tumors, which often affects elderly people who will likely die by
other causes. In addition, prostate cancer can be diagnosed earlier
and tumor evolution can currently be monitored by dosing the
PSA in serum, which is a safe, noninvasive, and cheap procedure.
In spite of the former advantages, however, prostate cancer is
known to produce local and/or distal recurrences in around a
quarter of the patients undergoing radical prostatectomy (RP; see
ref. 4) or radical radiotherapy (RRT), and salvage therapies may
become very critical for them. In recurrent prostate cancer, after a
variable time following the primary therapy (RP or RRT), a so-
called biochemical recurrence is observed, with a progressive rise
of the PSA values above or at 0.20 ng/mL after RP (see ref. 5).
Adjuvant therapy is sometimes prescribed just after RP or RRT.
One of the most frequent ones is the androgen deprivation
therapy (ADT). It abruptly reduces PSA values but normally fails
in the long-term control of the tumor, which possibly becomes
resistant to the therapy.
Predicting the probability of recurrence of prostate cancer after
RP is one of the main goals of the studies and researches in the
field. Roughly speaking, there are twomain ways of thinking: one
(static models) relates the recurrence probability and its timing to
the preoperative tumor characteristics (e.g., Gleason Score, tumor
stage, surgical techniques; see Table 1 for details) and so on,
whereas the second one (dynamic models) investigates the post-
operative tumor dynamics mainly based on the PSA growth
timing. Static models are normally validated on a huge clinical
database and aim at producing simple and reliable tools for
addressing therapeutic decisions. Very popular nomograms have
been proposed, starting from the first model of Partin and
colleagues (6), the GPSM (Gleason, PSA, seminal vesicle, and
margin status) proposed by Blute and colleagues (7), the nomo-
gram of Briganti and colleagues (8), and all their updated
versions.
Dynamic models focus on the estimation of PSA velocity and
doubling time, evaluating the timing of tumor proliferation
from serial PSA measurements (see refs. 9–11). More complex
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Major Findings
* In the mainframe of a validated tumor growth model
(1), the parameter (a) is a biologically sensible indicator
of the growth potentiality of the relapsed prostate
cancer.
* Provided only PSA-producing prostate cancer cells may
survive after radical prostatectomy (RP), a can be simply
estimated on a limited series of PSA values collected after
RP, and it proves to be a reliable and robust parameter for
predicting the time to relapse.
* In the absence of any adjuvant therapy, the numeric value
of a is inversely correlated (P < 0.0001) with the time to
relapse.
* When adjuvant androgen deprivation therapy (ADT) is
prescribed, a is still well correlated to the timing of
recurrence (P ¼ 0.0001), but its value is larger, probably
because ADT impacts on the prostate cancer cells'
metabolic pathways.
* When the tumor becomes resistant during ADT, a values
become even larger, reflecting a direct effect on the cell
metabolism.
* This biologically sensible mathematical model may help
clinicians in optimizing their follow-up data elaboration
to early predict (and possibly counteract) prostate cancer
recurrence.
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mathematical models were also proposed (e.g., see refs. 12–15),
considering the different behaviors of the various genotypes
involved, at least two types of cells, hormone sensitive and
hormone resistant, detected in recurrent prostate cancer.
As the prostate tumor growth is very slow, logistic and Gom-
pertzian growth laws have been normally preferred to the simpler
exponential curve. As a matter of fact, all the three mathematical
models previously cited belong to a general family of growth
models, as shown by the phenomenological universality (PUN)
approach (1), to which the generalized von Bertalanffy (16)
growth law also pertains:
dw
dt
¼ awm  Kwn ðBÞ
which assumes that the change of body weight w is given by the
difference between the processes of building up and breaking
down. a and K are constants of anabolism and catabolism,
respectively. The exponents m and n indicate a proportionality
to some power of the body weight w.
In this article, we will use the West and colleagues' (3) formu-
lation of Eq. B (see Quick Guide to Equations and Assumptions).
Note that the Gompertzian law is more used in modelling
prostate cancer, and also in this case, a correlation between the
parameters and the time to relapse canbe found (17).However, to
estimate the growth parameters for each patient, it is not easy to
manage. In fact, we developed in ref. 17 a new procedure,
combining radial basis functions and a stochastic optimization
method, to estimate the Gompertzian parameters. Here, we
exploit the fact that the parameter of theWest law can be obtained
analytically, without using complex numerical methods. More-
over, beyond the mathematical formalism, West and colleagues
showed that a strictly biological interpretation could be given to
the equation parameters, provided the originally indeterminate
power exponent value is restricted to the well-known Kleiber law
Table 1. Terminology
pGS Histologic scoring of the definite RP sample. pGS ranges from 2 to 10, with 2 representing the most well-differentiated tumors and 10 the
least-differentiated tumors. In our patient cohort, pGS ranges from 5 to 10, and 0 indicates that the value is not known.
Pathologic T stage Designates the size and invasiveness of the tumor. The number increases with tumor size and extent of invasiveness. For example, a
microscopic lesion confined to the prostate would be T1; macroscopic tumor confined to the prostate is T2; extended tumor beyond the
prostate (extracapsular extension or seminal vesicles invasion) is T3; and a massive tumor that directly invades adjacent organs (such as
rectum and bladder) is T4. In our patient cohort, T stage assumes the values T2 and T3.When the stage is not known, we use the acronym
"NA."
pN N0 means that the cancer has not spread to any lymph nodes, N1 means the cancer has spread to nearby lymph nodes in the pelvis.
Surgery techniques Retropubic, laparoscopic, or robotic.
Postoperative PSA PSA is a protein produced exclusively by prostate cells. In case of prostatectomy, the value should be near to zero. The threshold of the
biochemical relapse is 0.2 ng/mL. If the first PSA value after prostatectomy is equal to or greater than 0.2 ng/mL, local recurrences or
metastases are already present.
Positive margins Tumor extending to the surgical margin (inked surface at the pathologic exam).
Abbreviations: pGS, pathologic Gleason score; pN, regional lymph nodes.
Quick Guide to Equations and Assumptions
As shown by Castorina and colleagues (2), living beings grow according to a common phenomenological universal growth law
(PUN), which includes most of the models commonly used (e.g., exponential, Gompertzian,. . .).
In this article, we focus on a second-order solution of the PUN and apply it to model the PSA dosage p collected at time t, which
reflects the biochemical activity of the hormone-sensitive cell population surviving after radical prostatectomy:
dp
dt
¼ ap
3
4 1 p
P
 14" #
ðAÞ
where p is the PSA value (in ng/mL), P is its limiting value or carrying capacity (in our case P ¼ 100 ng/mL), t is the time of the
measurement expressed in months after surgery, and a is the growth parameter for PSA. Note that Eq. A corresponds to the von
Bertalanffy law (Eq. B), where K ¼ 1/P, m ¼ 3/4, and n ¼ 1.
Physical data can be renormalized following simple calculations (see ref. 3 for the details), in terms of rescaled fraction r¼ (p/P)1/4
and rescaled time t ¼ a t/4P1/4  ln[1-(p0/P)1/4], where p0 is the initial value of the series.
Far from being mathematical tricks, the rescaled units allow us a quick comparison between our experimental data and the
parameter-less universal curve r ¼ 1  et, obtained by substituting r and t in the solution of Eq. A. PSA data being very scattered
and their time correlation very poor, the a parameter value was evaluated deterministically as:
a ¼ 4P1=4log 1
p0
P
  log 1 pP 
t
where (p, t) are the PSA values and the times of the measurement, respectively. Note that the physical dimensions of a are
ng0.25mL0.25month1. In principle, a is estimated by all the patient's PSA collection, but in this article, we also investigated the
case of fixed values of PSA (i.e., ref. 4) to implement a practically useful algorithm. In the case of adjuvant ADT, which tends to
depress the PSA value and the tumor volume, a was calculated from the set of PSA values taken after the end of the therapy.
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ratio 3/4 (18),which relates the body growthwith the age inmany
animal species, n ¼ 1 and K ¼ a W1/4, W being the carrying
capacity. This law was already applied to tumors in both theo-
retical and applied mathematical models (1, 19, 20), while the
choice of a different value of the exponentK¼aW1/3 is preferred
in case of multicellular tumor spheroids and tumor cords, where
cells keep their nutrients from their surface (21).
In this article, we propose to extend its application to investi-
gate how the PSA production grows in recurrent prostate cancer,
based on the fact that tumor volume is strictly related to PSA
production in radically prostatectomized patients (10, 21). In
particular, we focus our attention on the growth parameter (see
the Quick Guide to Equations and Assumptions for further
details), which reflects the proliferation of surviving prostate
cancer cells after RP andmay be evaluated by the resulting overall
PSA production. According to West and colleagues, a is the ratio
between the metabolic energy and the energy needed for dupli-
cation of a given cell type. In the case of PSA production, it is
expected to increase when cells actively produce PSA and repro-
duce themselves. On the contrary, it is expected to decrease when
cells produce small amounts of PSA and duplicate slowly. As
prostate cancer cellmetabolism is regulatedby androgen-sensitive
agents, any intervention on the hormonal drive is expected to
impact on the metabolic energy and therefore on the value
estimated after such therapy. The acronym ADT (androgen dep-
rivation therapy) actually defines different pharmacologic com-
pounds primarily aiming at inhibiting the androgen biosynthesis,
blocking the enzymes responsible for testosterone and estrogen
synthesis or the receptor–ligandbinding (see ref. 22). By our point
of view, more than assessing the difference in clinical outcome,
ADT is of great importance as it is expected to modify the
metabolic level of the prostate cancer cells, challenging ourmodel
to accommodate PSA data reflecting a different metabolic status.
In the Clinical data section, the available data are presented.
In the Statistical analysis section, the values of the a parameter
are inserted together with those of the standard clinical para-
meters in a statistical multiparametric analysis to estimate how
each parameter impacts on the overall predictability and the
timing of recurrence on retrospective data. In the Results
section, the study is extended to the relapsed patients who
underwent adjuvant ADT. In the Discussion section, a brief
discussion is proposed, and conclusions are given in the Con-
clusions section.
Materials and Methods
Clinical data
Eureka1 study (23) collected data from 3,538 patients treated
by a prostatectomy (radical, nerve-sparing, uni- and bilateral) as
primary therapy. The majority of them (2,831) did not undergo
adjuvant ADT and only 473 (17%) relapsed.
For data inclusion in this study, further screening procedures
were performed on the basis of both clinical and computational
requirements:
* We only accounted for patients treated with radical
prostatectomy, excluding the nerve-sparing surgeries because
of possible noncancerous PSA-producing prostate cells
remnants.
* We excluded the patients whose first PSA after surgery was
larger than 0.2 ng/mL, as either their primary tumor was not
properly removed or metastases were already present.
* Finally, to calculate the a parameter (see Quick Guide to
Equations and Assumptions), we considered only the
relapsed patients with at least 4 PSA values reported in their
follow-up.
Statistical analysis
Amultivariate statistical analysis was performed with SAS (SAS
Institute Software) using the time to relapse as dependent variable
and the values of all the postsurgically available parameters
(Gleason score, pathologic stage, type of surgery, margins, and
lymph node metastasis) plus the coefficient, calculated as
described in the previous subsection, as independent variables.
Themultivariate analysis was repeated by progressively exclud-
ing the nonstatistically significant parameters. Moreover, the
predictive value of the parameter calculated on the whole PSA
series (from 4 to 17 values measured during the follow-up, i.e.,
from2 to10years after surgery)was comparedwith that estimated
using only the first 4 PSA values recorded after biochemical
failure. Wherever possible, data were inserted into the model as
continuous variables, so that the corresponding parameter esti-
mate computed by the model was the actual slope of the straight
line on which the data were fitted. The sign of the parameter
estimate determined whether the dependent variable increased
(þ) or decreased () with respect to the independent one; the
absolute value determined the steepness of the slope. Qualitative
as well as quantitative variables that were not continuously
distributed in their range were inserted as dummies.
Results
The a parameter
In this subsection, we refer to Figs. 1 and 2 (white dots and
light lines). For RP patients, the statistical analysis (see
the Table 2) shows that the time to relapse does not depend
on any clinical information apart from the a parameter (see Fig.
1, white dots). In particular, a is highly predictive of the range
of the time to relapse, with the smaller a values being predictive
for a longer disease-free time. In Fig. 1, the white circles
represent the values of a versus the time to relapse. The
intercept (the light one) has P < 0.001.
Note that the value of a is not strictly related to the month of
relapse but can predict the period of the relapse very well. In
particular, we want to distinguish early relapses, that is, before 2
years (24months) after RP, to late relapses, that is, after 4 years (48
months). These thresholds can be used by clinicians to plan the
follow-up visits and the (adjuvant) therapies.
In our sample,we found that 0<a<0.01 implies T>48months
with a probability of 62%and T > 36monthswith a probability of
93.6%. The a values ranging between 0.01 and 0.02 were not a
strong predictor; in fact, 61.1% of patients relapse before 36
months and 22% after 48 months. Larger values (0.02 < a <
0.04) imply T < 48months with a probability of 100% and T < 24
in 78.9% of cases. a > 0.04 implies T < 24 months with a
probability of 100%.
We then considered the patients who underwent ADT for at
least 6months, collecting the PSA values after the end of the ADT,
and excluding those who relapsed before the treatment period.
Also among them, we noticed a correlation between the duration
of the therapy and the value; in particular, a was perfectly
correlated to the time to relapse, with no exceptions, when the
treatment period is longer than one year. In Fig. 2, thewhite circles
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represent the values of a versus the time to relapse. The intercept
(the light one) has P < 0.001.
In this cohort, 0 < a  0.01 implies T > 48 months in 72.7%
of cases and 100% if the adjuvant therapy is given for more
than 12 months. a 0.01 implies T < 24 in 30% of cases, 24 < T
< 48 in 50%, and T < 48 months in 80%. When the adjuvant
therapy is given for more than 12 months, all the patients
relapsed within 24 months. As a matter of fact, in 27.1% of
treated patients, relapse occurred before the end of the adjuvant
ADT. Although ineffective from a clinical point of view, for
these patients, a change in the metabolism of the cells is
apparent, as the a values are larger than in the remaining
72.9% (0.01–0.065 instead of 0.0002–0.02).
Optimization of the algorithm for clinical trials: the a4
parameter
In this subsection, we refer to Figs. 1 and 2 (dark dots and
marked lines).
After showing that the a parameter is very well correlated to
the time to relapse, the use in clinical practice should be
encouraged by proposing simple and robust evaluation algo-
rithms. Looking at the Quick Guide to Equations and Assump-
tions, a parameter is calculated using all the available data, that
is, also those collected after relapse. In clinical practice, how-
ever, time to relapse should be predicted on the basis of only
prerelapse data! We therefore investigated the reliability of the
estimation of a using only the a limited number of PSA values
collected before relapse, with a maximum of 4. We call this
estimation as a4. The a4 value has the same behavior as a, and
the two parameters can be compared as shown in Figs. 1 (no
ADT cohort) and 2 (ADT cohort). The colored circles represent
the values of a4 versus the time to relapse. The intercept (the
more marked one) has P < 0.001. In the nontreated cohort, in
fact, we found that 0 < a4 < 0.01 implies T > 48 months with a
probability of 54% and T > 36 months with a probability of
82%. The a4 between 0.01 and 0.02 is not a strong predictor as
a; in fact, 55.1% of patients relapse before 36 months and 24%
after 48 months. 0.02 < a4 < 0.04 implies T < 48 months with a
probability of 95.2% and T < 24 in 71.4% of cases. a4 > 0.04
implies T < 24 months with a probability of 93.3% and T < 12
months with a probability of 86.6%.
In the hormone-treated cohort, 0 < a4  0.01 implies T > 36
months in 61.5% of cases. a4  0.01 implies T < 24 in 33.3% of
cases, 24 < T < 48 in 50%, and T < 48 months in 83.3%. When
adjuvant therapy was given for more than 12 months, all the
patients relapsed after 24 months.
Discussion
Relevant information seems to be hidden in the values of the a
parameter evaluated on the PSA collection after RP, which are
substantially retained also by a4. According to ref. 3, a is originally
related to the ratio between the metabolic energy required by the
cell and the energy needed for duplication:
a ¼ B
E
where B is proportional to themetabolic rate of a single cell, and E
is the metabolic energy required to create a cell. In Fig. 3, the
estimated a in 4 paradigmatic patients, treated by adjuvant
ADT for at least 6 months, is shown. Original data are provided
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Figure 1.
No adjuvant therapies: a versus time to relapse (white dots) compared
with a4 versus time to relapse (dark dots). Both a anda4 have a good correlation
with the time to relapse. The results of the estimation of a and a4 are
comparable.
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ADT for at least 6 months: a versus time to relapse (white dots) compared
with a4 versus time to relapse (dark dots). Both a anda4 have a good correlation
with the time to relapse. The results of the estimation of a and a4 are
comparable.
Table 2. Output of the multivariate analysis between clinical parameters in the
case of no adjuvant therapies (SAS Software)
df b coefficient F value P > F
Gleason score 4 1.5670 0.61 0.6566
Pathologic stage 4 4.0526 1.58 0.1856
pN 1 0.5884 0.92 0.3407
Postsurgery PSA 1 1.2551 1.95 0.1651
Positive margins 1 2.0849 3.24 0.0744
a class 5 38.6463 12.03 <0.001
NOTE: Gleason score, pathologic stage, pN, PSA after surgery, presence of
positive margins, and the a class were considered as predictive variables for the
time to relapse. As shown, only the a parameter is statistically correlated to the
time to relapse.
Abbreviations: df, degrees of freedom; pN, regional lymph nodes.
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in Table 3. PSA values are rescaled by r and t as explained in the
Quick Guide to Equations and Assumptions. Dots indicate the
PSA values during adjuvant ADT, and stars indicate posttherapy
PSA values (free growth). The black line represents the expected
theoretical growth r ¼ 1 et .
The dispersion of a is obviously related to the differences in
individual growth and/or metabolic status of the recurrent
tumors. It seems a reasonable fact that larger values of a correlate
with faster growth, corresponding to lesser energy need for cell
replication. These results suggest that some quantitative measure-
ments of proliferation parameters, such as Ki67, would be helpful
to drive clinical management.
The effect of ADT on cell metabolism is evident as well. It is
well known that hormones play an important role in optimiz-
ing cell metabolism. A complete abolition of the hormonal
drive is therefore reflected by a severe reduction of B during the
therapy (see the dots in Fig. 3). Note that in some cases (see Fig.
3A–C), the effect remains for many months after the end of the
therapy.
As soon as the normal metabolic paths are restored, however,
three behaviors can be observed. The more frequent one is that
the normal a value is quickly recovered and PSA data would
regain their expected ranges (see stars in Fig. 3A and C). In Fig.
3B, PSAs remain under the theoretical curve: this could mean
that adjuvant therapy has had a "retarding" effect on relapse.
The latter behavior is shown in Fig. 3D: the tumor growth seems
to be faster than expected, suggesting a sort of catch-up effect,
which is common when dietary limitations are suddenly
stopped. The a values, however, are smaller following ADT,
possibly because the cell metabolic rate changed or part of the
tumor-proliferating cells stops producing PSA following an
epigenetic (adaptation) or genetic (mutation) event (24). As
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Figure 3.
Estimated in four patients (A–D)
treated by adjuvant (adj) ADT,
indicated in the legend as hormone
therapy (HT), for at least 6 months.
PSA values are rescaled by r and t.
Dots, PSA values during adjuvant
ADT; stars, posttherapy PSA values
(free growth). Black line, expected
theoretical growth r ¼ 1 et . Data
were collected during the Eureka1
study from prostatectomized human
patients.
Table 3. PSA data of the four patients in Fig. 3
Patient 1
Months 6 16 31 40 53 68 80 88
PSA 0 0 0 0 0 0 0.06 0.52
Patient 2
Months 4 10 27 37 54 63 76 88 123
PSA 0 0 0 0 0 0.12 0.68 1.15 2.39
Patient 3
Months 1 4 9 16 23 31 39 45 53 56 59 64
PSA 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.07 0.22 0.49 0.81 2.32
Patient 4
Months 3 10 16 22 28 32 33 35 39
PSA 0.1 0.1 0.1 0.1 0.1 8.1 7.7 17 36.5
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a matter of fact, the increase of the a values in early relapsing
ADT patients suggests that some mutations have occurred.
We need to understand this point better, but our hypothesis
is that as therapy lowers the proliferation of cells, the tumor
cannot keep on growing at the same speed, and a part of its
initial energy is spent to restore its metabolic status instead of
promoting growth.
The opposite behavior appears in the case of resistance to ADT:
growth is faster than without therapy. The death of hormone-
dependent cells favors the independent ones to mutate and
proliferate, because of the sudden availability of space and nutri-
ents. The samebehavior iswell described byHanin and colleagues
(25) when primary tumor removal allows a growth spurt of the
metastasis. Hence, ADT increases the aggressiveness of the tumor
and relapse is very fast.
An interesting comparison can be done among the values of the
parametera in case of ADT andnoADT (see Fig. 4A). The values in
case of no ADT seem to be smaller, but the frequency of time to
relapse (Fig. 4B) is the same in both cohorts. Thismeans that ADT,
if successful, tends to make the tumor less aggressive. However, a
spread of growth is observed when it is unsuccessful. In fact, by
selecting some patients who had a relapse during adjuvant ADT,
we found that the parameter values were higher than in the other
cases: 0.01 to 0.065 instead of 0.0002 to 0.02. It suggests that a
mutation occurred, which implied a change in the metabolism of
the cells.
Conclusions
The a parameter, estimated on the basis of at least 4 PSA
dosages after RP, is a reliable, robust, and easily evaluable index,
which is strongly related to the timing of prostate cancer recur-
rence in RP patients. Moreover, a is still a good predictor even
when the patients were treated with adjuvant ADT.
The combination of a careful collection of PSA values and a
biologically sensible computational model, possibly corrob-
orated with tumor kinetics information, would be a valuable
tool that overcomes the other traditional clinical parameters
(such as pGS, pathologic staging, etc.) in predicting the
timing of tumor recurrence. Future works will aim at creating
a simple and friendly tool for clinicians able to automatically
estimate a from the PSA series. This program should show the
possible scenarios and help in planning a more effective and
personalized therapy. Moreover, this calculation could be
computed by a PC or laptop in a hospital, that is, the tool
will be easily available. We could hence provide a biologically
meaningful and practical parameter for promoting personal-
ized medicine in this and possibly in other fields of
application.
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